Overall, the data presented in our study support the value of immunophenotyping as a fast and reliable method to achieve information on prognosis in AML in general and identify CD105 as a novel prognostic marker for adverse disease course in particular. The gene discussed is ENG; the disease is acute myeloid leukemia.